Asia · Regional markets · Mint

Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

Published by Mint · India 53 min ago

JM Financial initiated coverage of Symbiotec Pharmalab with a Buy rating and a ₹1,622 target price, implying about 27% upside. It expects new capacity, CDMO and complex injectable…

Read the full article on Mint Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.livemint.com)

Also worth reading

CNBC-TV18

Raymond Q2 Results: Net profit more than doubles to ₹32 crore as revenue grows 24%

Tech in Asia

Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

Share

Also worth reading

Raymond Q2 Results: Net profit more than doubles to ₹32 crore as revenue grows 24%

NTU, VFT launch $11.7m lab for grid-scale batteries

OCBC is Asia-Pacific’s strongest bank and third globally: The Asian Banker

Labubu loses its bite as Pop Mart’s quarterly sales plunge up to 50%

Korea’s housing wealth gap hits record 290-fold

Tata Motors’ Iveco takeover gets 87.8% acceptance